Merck & Co., Inc. (NYSE:MRK) Price Target Raised to $160.00

Merck & Co., Inc. (NYSE:MRK) had its price target boosted by The Goldman Sachs Group from $140.00 to $160.00 in a report issued on Friday morning,Benzinga reports. The Goldman Sachs Group currently has a buy rating on the stock.

Several other analysts have also recently issued reports on MRK. Citigroup initiated coverage on shares of Merck & Co., Inc. in a report on Wednesday, May 6th. They issued a “neutral” rating and a $125.00 price target on the stock. Jefferies Financial Group downgraded Merck & Co., Inc. from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 19th. Weiss Ratings cut shares of Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research report on Tuesday, August 11th. Guggenheim lifted their price objective on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Finally, Morgan Stanley upgraded shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $116.00 to $179.00 in a research note on Thursday. Fifteen investment analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $144.10.

Merck & Co., Inc. Stock Performance

NYSE MRK opened at $152.43 on Friday. Merck & Co., Inc. has a fifty-two week low of $77.58 and a fifty-two week high of $154.49. The stock has a market cap of $376.07 billion, a price-to-earnings ratio of 121.94, a price-to-earnings-growth ratio of 6.40 and a beta of 0.19. The business has a fifty day moving average of $128.09 and a 200-day moving average of $121.29. The company has a quick ratio of 1.10, a current ratio of 1.32 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The company had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. During the same period in the prior year, the firm posted $2.13 earnings per share. The firm’s revenue was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts predict that Merck & Co., Inc. will post 2.76 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. The ex-dividend date of this dividend is Tuesday, September 15th. This represents a $3.40 annualized dividend and a dividend yield of 2.2%. Merck & Co., Inc.’s dividend payout ratio is currently 272.00%.

Insider Activity at Merck & Co., Inc.

In other news, EVP David Michael Williams sold 52,847 shares of the firm’s stock in a transaction on Wednesday, August 5th. The stock was sold at an average price of $128.77, for a total transaction of $6,805,108.19. Following the completion of the sale, the executive vice president directly owned 31,716 shares of the company’s stock, valued at $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Chirfi Guindo sold 10,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $135.00, for a total value of $1,350,000.00. Following the completion of the transaction, the executive vice president owned 36,613 shares in the company, valued at $4,942,755. The trade was a 21.45% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 228,238 shares of company stock worth $29,977,783. 0.17% of the stock is owned by corporate insiders.

Institutional Trading of Merck & Co., Inc.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Round Rock Advisors LLC grew its stake in shares of Merck & Co., Inc. by 0.7% during the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after buying an additional 66 shares during the last quarter. Cascade Financial Partners LLC lifted its stake in shares of Merck & Co., Inc. by 0.5% in the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after acquiring an additional 80 shares during the last quarter. Somerset Trust Co lifted its stake in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Somerset Trust Co now owns 8,701 shares of the company’s stock valued at $1,118,000 after acquiring an additional 81 shares during the last quarter. Stonebridge Financial Group LLC lifted its stake in shares of Merck & Co., Inc. by 0.9% in the 2nd quarter. Stonebridge Financial Group LLC now owns 8,747 shares of the company’s stock valued at $1,124,000 after acquiring an additional 81 shares during the last quarter. Finally, Stronghold Wealth Management L.L.C. boosted its holdings in shares of Merck & Co., Inc. by 2.6% during the 2nd quarter. Stronghold Wealth Management L.L.C. now owns 3,237 shares of the company’s stock valued at $416,000 after acquiring an additional 82 shares in the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Stories Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their personalized cancer therapy met key Phase 3 goals, improving recurrence-free and distant metastasis-free survival for high-risk melanoma patients when added to Keytruda. The result is the first major late-stage win for an mRNA cancer vaccine and strengthens the potential for regulatory approval and broader oncology applications. MRK/MRNA’s Personalized Cancer Therapy Delivers First Phase III Win
• Positive Sentiment: Several Wall Street firms raised their outlooks for MRK: Goldman Sachs increased its price target to $160 and kept a Buy rating, while BMO raised its target to $170 and UBS lifted its target to $175. Morgan Stanley also upgraded the shares to Overweight with a $179 target after the cancer-trial success.
• Positive Sentiment: Investors see Merck’s newer products, acquired assets and pipeline programs as a potential growth cushion against Keytruda’s eventual patent expiration. The company’s expanding portfolio could help diversify revenue beyond its flagship drug. Can Merck’s New Drugs Offer Growth Cushion Ahead of Keytruda LOE?
• Neutral Sentiment: Unusually high options activity indicates heightened investor interest and potential volatility, but it does not by itself establish the direction of the stock.
• Negative Sentiment: RBC Capital Markets downgraded Merck to Sector Perform and set a $150 target, arguing that execution risks and the 2028 Keytruda loss of exclusivity are being underestimated. RBC said near-term catalysts are attractive, but the stock’s valuation leaves limited room for additional gains. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Negative Sentiment: Jefferies separately moved Merck from Strong Buy to Hold. The central concern is that the shares have already rallied substantially on the trial news, making the current valuation appear demanding relative to the remaining patent and execution risks.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.